Fig. 8
From: METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression
METTL16/SOGA1 axis are clinically relevant with poor prognosis in CRC patients. A CCK8 assay was conducted to measure proliferation of SW620-OEM16 cells transfected with siSOGA1. B Transwell assays were conducted to measure migration and invasion of SW620-OEM16 cells transfected with siSOGA1. C Xenografts derived from SW620-OEM16 or SW620-OEM16-shSOGA1/shPDK4 cells and relative controls (n = 6). D, E Tumor volume was recorded at indicated time to establish a growth curve (D) and tumors weight (E) were measured after mice sacrificed. (F) Representative images of METTL16, SOGA1, pAMPK, and PDK4 IHC staining in CRC tissues. G Correlation analysis between METTL16 and SOGA1 protein expression based on IHC staining scores. H Kaplan-Meier survival curves of OS based on METTL16/SOGA1 or METTL16/PDK4 IHC staining in CRC patients. I A working model of METTL16-promoted SOGA1 m6A modification in CRC progression. **P < 0.01, ***P < 0.001